News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Serentis Starts Phase II Trial with First-in-Class SRD441 for Eczema



4/7/2009 10:17:03 AM

CAMBRIDGE, United Kingdom--(BUSINESS WIRE)--Serentis, a privately owned biopharmaceutical company, announced today that it has commenced patient recruitment in a Phase II clinical trial for atopic dermatitis (AD), a type of eczema.

Read at BioSpace.com


comments powered by Disqus
Serentis
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES